white paper

5 innovative new drugs to expect soon

View the Q4 2020 Drug Pipeline Insights Report 


At OptumRx, we are committed to providing our clients, members and the broader healthcare community with up-to-date information and support regarding drug access, cost management, and notable FDA approvals.

In our last report, we noted delays in drug development and postponement of FDA submissions due to COVID-19. In this report, we outline reasons why delays may be the exception and the COVID-19 impact to drug development is minimal. 

See the 5 new and innovative drugs expected to have FDA approval soon.  


Don't want to read the full report? Download the brief summary.